Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies [0.03%]
揭秘前列腺癌免疫治疗:了解当前和未来的治疗策略
Ravi A Madan,James L Gulley,Philip W Kantoff
Ravi A Madan
Immunotherapy has emerged as a viable therapeutic option for patients with prostate cancer. There are multiple potential strategies that use the immune system, including therapeutic cancer vaccines that are designed to stimulate immune cell...
Dana Rathkopf,Howard I Scher
Dana Rathkopf
Persistent androgen receptor (AR) signaling despite low levels of serum androgens has been identified as a critical target for drug discovery in castration-resistant prostate cancer (CRPC). As proof of principle that the AR remains relevant...
Agents that target androgen synthesis in castration-resistant prostate cancer [0.03%]
靶向雄激素合成的治疗药物在去势抵抗性前列腺癌中的应用
Roberta Ferraldeschi,Johann de Bono
Roberta Ferraldeschi
In April 2011, abiraterone acetate (in combination with low-dose steroids) was approved by the US Food and Drug Administration for the treatment of men with metastatic, castration-resistant prostate cancer who have previously been treated w...
Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer [0.03%]
潜在的预测生物标志物可对男性去势抵抗性前列腺癌的治疗进行个体化治疗
Rhonda L Bitting,Andrew J Armstrong
Rhonda L Bitting
With the surge in therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specifi...
Ajjai Alva,Maha Hussain
Ajjai Alva
Since 1941, the understanding of prostate cancer pathogenesis and therapy has undergone a significant transformation. Rigorous translational research has identified multiple mechanisms underlying castration resistance, the fatal clinical st...
From the guest editor: progress in the treatment of advanced prostate: new data and horizons [0.03%]
本期客座主编述评:晚期前列腺癌治疗进展:新数据和展望
Oliver Sartor
Oliver Sartor
USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer [0.03%]
新辅助治疗后乳腺癌患者中USP-11的预后和预测价值
Soley Bayraktar,Angelica M Gutierrez Barrera,Diane Liu et al.
Soley Bayraktar et al.
Purpose: USP-11, a member of the ubiquitin-specific protease family, has emerged as an essential regulator of double-strand break repair. Few studies have shown that silencing USP-11 led to hypersensitivity to poly(ADP-ri...
Quality of cancer survivorship care in the military health system (TRICARE) [0.03%]
军事卫生系统(TRICARE)中癌症幸存者护理的质量
Justin P Fox,Diana D Jeffery,Thomas V Williams et al.
Justin P Fox et al.
Purpose: Following the acute phase of treatment, national guidelines recommend cancer survivors have routine contact with health care providers and undergo basic ancillary testing while avoiding high-cost imaging (HCI). W...
Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box" [0.03%]
胰腺癌的分子治疗和替代疗法:“跳出思维定势”
Renee Tholey,Janet A Sawicki,Jonathan R Brody
Renee Tholey
The current treatment options for pancreatic ductal adenocarcinoma fall exceedingly short of a cure, providing a sobering 5-year survival rate of only 5% for all patients, and the disease will be responsible for more than 37,000 deaths in t...
Pelin Cinar,Margaret A Tempero
Pelin Cinar
Pancreatic cancer continues to be a challenging disease to treat because of its aggressive nature, advanced stage at the time of diagnosis, and limited treatment options that are available. Traditional cytotoxic chemotherapy provides modest...